Suppr超能文献

54 例神经性咳嗽患者的喉上神经阻滞反应率。

Superior Laryngeal Nerve Block Response Rates in 54 Neurogenic Cough Patients.

机构信息

Department of Otolaryngology-Head and Neck Surgery, The Ohio State University College of Medicine, Columbus, Ohio, USA.

Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

出版信息

Laryngoscope. 2023 Oct;133(10):2647-2653. doi: 10.1002/lary.30570. Epub 2023 Jan 23.

Abstract

OBJECTIVE

Neurogenic cough related to hypersensitivity of the internal branch of the superior laryngeal nerve (SLN) is often treated with neuromodulating medications, which can cause considerable side effects. An alternative therapy is steroid and local anesthetic injection of the SLN ("SLN block"), initially proposed to benefit those with lateralizing symptoms (tenderness over the thyrohyoid membrane or unilateral cough source). Our objectives are to determine if SLN block produces subjective symptomatic improvements and if repeat injections further improve symptoms, and evaluate clinical factors potentially predictive of response.

METHODS

Retrospective chart review of 54 patients receiving SLN blocks at a tertiary medical academic center from January 2010 to June 2020. Medical history and anticipated predictors of positive response, including stigmata of laryngeal hypersensitivity, were recorded. Outcomes included symptomatic response, number of injections required, and side effects. Response was defined subjectively by asking patients whether the injection was beneficial and objectively by using CSI scores.

RESULTS

Fifty-four patients met the inclusion criteria. Thirty-eight patients (70.4%) endorsed improvement. No variables were identified as positive predictors of response. Thirty-two of the 38 (84.2%) endorsed improvement after one injection. Six of 15 (40%) patients who failed the first injection had positive response to the second. No significant side effects were reported.

CONCLUSION

No localizing symptoms, specific cough features, or aspects of the medical history helped predict response, suggesting that a broader range of patients may be offered the intervention. The majority of patients reported symptomatic improvement and repeat injections may benefit patients with initial nonresponse.

LEVEL OF EVIDENCE

4 Laryngoscope, 133:2647-2653, 2023.

摘要

目的

与喉上神经(SLN)内支过敏相关的神经性咳嗽常采用神经调节药物治疗,但可能会产生较大的副作用。另一种替代疗法是 SLN 的皮质类固醇和局部麻醉注射(“SLN 阻断”),最初是为那些有侧化症状(甲状舌骨膜压痛或单侧咳嗽源)的患者设计的。我们的目的是确定 SLN 阻断是否会产生主观症状改善,以及重复注射是否会进一步改善症状,并评估可能预测反应的临床因素。

方法

回顾性分析 2010 年 1 月至 2020 年 6 月在一家三级医学学术中心接受 SLN 阻断的 54 例患者的病历。记录了病史和预期的阳性反应预测因素,包括喉过敏的征象。结果包括症状反应、所需注射次数和副作用。通过询问患者注射是否有益来主观判断反应,通过 CSI 评分来客观判断反应。

结果

54 例患者符合纳入标准。38 例(70.4%)患者表示有改善。没有发现任何变量是反应的阳性预测因素。38 例中有 32 例(84.2%)在第一次注射后表示有改善。第一次注射失败的 15 例患者中有 6 例(40%)对第二次注射有反应。没有报告明显的副作用。

结论

没有定位症状、特定的咳嗽特征或病史的任何方面有助于预测反应,这表明可以为更广泛的患者提供该干预措施。大多数患者表示症状改善,重复注射可能对初次无反应的患者有益。

证据水平

4 级喉镜检查,133:2647-2653,2023 年。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验